TY - JOUR
T1 - Association of low-density lipoprotein pattern with mortality after myocardial infarction
T2 - Insights from the TRIUMPH study
AU - Pokharel, Yashashwi
AU - Tang, Yuanyuan
AU - Bhardwaj, Bhaskar
AU - Patel, Krishna K.
AU - Qintar, Mohammed
AU - O'Keefe, James H.
AU - Kulkarni, Krishnaji R.
AU - Jones, Peter H.
AU - Martin, Seth S.
AU - Virani, Salim S.
AU - Spertus, John A.
N1 - Funding Information:
J.H.O'K. is on the speaker's bureau for Amgen and Regeneron and has a major ownership interest in Cardiotabs. K.R.K. was a former employee of Atherotech Diagnostics Lab. P.H.J. is a chief scientific officer of the National Lipid Association. S.S.M. is a co-inventor on a pending patent filed by Johns Hopkins University for novel LDL-C estimation. He has served as a consultant to Quest Diagnostics, Sanofi-Regeneron, Amgen, Pressed Juicery, Abbott Nutrition, and Pew Institute. He has received honoraria from the American College of Cardiology for lipid-related activities. He has received research support from the American Heart Association, Aetna Foundation, CASCADE FH, Google, and Apple. S.S.V. is supported by the Department of Veterans Affairs Health Services Research and Development Service (HSR&D), American Heart Association Beginning-Grant-in-Aid, the American Diabetes Association Clinical Science and Epidemiology Award, and Baylor College of Medicine's Global Initiatives (paid to institution and not individual). He serves on the steering committee (no financial remuneration) for the Patient and Provider Assessment of Lipid Management (PALM) Registry at the Duke Clinical Research Institute. He has received honorarium from the American College of Cardiology for service as an Associate Editor for Innovations, acc.org. J.A.S. has received grant funding from Patient-Centered Outcomes Research Institute (PCORI), Abbott Vascular, Lilly; has an equity interest in Health Outcomes Sciences. The remaining authors have no relevant relationships to disclose.
Funding Information:
Y.P., K.K.P., and M.Q. are supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number T32HL110837.
Funding Information:
TRIUMPH study was funded by National Heart, Lung, and Blood Institute grant ( P50 HL077113 ) and CV Outcomes, Kansas City, Missouri.
Publisher Copyright:
© 2017 National Lipid Association
PY - 2017/11
Y1 - 2017/11
N2 - Background Studies of incident coronary heart disease risk within low-density lipoprotein (LDL) subclass (small, dense vs large, buoyant) have shown mixed results. No prospective cohort study has examined the association of small, dense, or large, buoyant LDL with mortality after myocardial infarction (MI). Objective The objective of the study was to examine association of LDL pattern after MI and death. Methods In 2476 patients hospitalized for MI, LDL pattern (A [large, buoyant], A/B [mixed], and B [small, dense]) was established by ultracentrifugation using Vertical Auto Profile. Using time-to-event analysis, we examined the association with 5-year mortality within LDL patterns, after adjusting for important patient and treatment characteristics. We additionally adjusted for LDL cholesterol (LDL-C) and triglyceride levels and used directly measured LDL-C and non-high-density lipoprotein cholesterol as exposures. Results Patterns A, A/B, and B were present in 39%, 28%, and 33% of patients, respectively, with incident rates (per 1000 patient-years) of 50, 34, and 24 for all-cause and 24, 19, and 10 for CV mortality. The hazard ratios (95% confidence interval) with LDL patterns A/B and B compared with pattern A were 0.77 (0.61, 0.99) and 0.67 (0.51, 0.88) for all-cause, 0.94 (0.67, 1.33) and 0.69 (0.46, 1.03) for cardiovascular, and 0.64 (0.45, 0.91) and 0.65 (0.45, 0.93) for noncardiovascular mortalities, respectively. Results were similar when further adjusted for LDL-C and triglycerides, or with LDL-C and non-high-density lipoprotein cholesterol as exposures. Conclusion Compared with LDL pattern A, pattern B was significantly associated with reduced all-cause and non-CV mortalities with a trend for lower CV mortality after MI, independent of LDL-C and triglycerides.
AB - Background Studies of incident coronary heart disease risk within low-density lipoprotein (LDL) subclass (small, dense vs large, buoyant) have shown mixed results. No prospective cohort study has examined the association of small, dense, or large, buoyant LDL with mortality after myocardial infarction (MI). Objective The objective of the study was to examine association of LDL pattern after MI and death. Methods In 2476 patients hospitalized for MI, LDL pattern (A [large, buoyant], A/B [mixed], and B [small, dense]) was established by ultracentrifugation using Vertical Auto Profile. Using time-to-event analysis, we examined the association with 5-year mortality within LDL patterns, after adjusting for important patient and treatment characteristics. We additionally adjusted for LDL cholesterol (LDL-C) and triglyceride levels and used directly measured LDL-C and non-high-density lipoprotein cholesterol as exposures. Results Patterns A, A/B, and B were present in 39%, 28%, and 33% of patients, respectively, with incident rates (per 1000 patient-years) of 50, 34, and 24 for all-cause and 24, 19, and 10 for CV mortality. The hazard ratios (95% confidence interval) with LDL patterns A/B and B compared with pattern A were 0.77 (0.61, 0.99) and 0.67 (0.51, 0.88) for all-cause, 0.94 (0.67, 1.33) and 0.69 (0.46, 1.03) for cardiovascular, and 0.64 (0.45, 0.91) and 0.65 (0.45, 0.93) for noncardiovascular mortalities, respectively. Results were similar when further adjusted for LDL-C and triglycerides, or with LDL-C and non-high-density lipoprotein cholesterol as exposures. Conclusion Compared with LDL pattern A, pattern B was significantly associated with reduced all-cause and non-CV mortalities with a trend for lower CV mortality after MI, independent of LDL-C and triglycerides.
KW - Density
KW - Low-density lipoprotein pattern
KW - Mortality
KW - Myocardial infarction
KW - Paradox
KW - Size
UR - http://www.scopus.com/inward/record.url?scp=85031429732&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2017.09.002
DO - 10.1016/j.jacl.2017.09.002
M3 - Article
C2 - 29050980
AN - SCOPUS:85031429732
SN - 1933-2874
VL - 11
SP - 1458-1470.e4
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 6
ER -